A preclinical project designed to treat Huntington’s disease has received £35 million in Series A financing on early evidence that it can slow or even halt progression of the disease. Huntington’s is an inherited disorder that attacks areas of the brain that help control movement. The funding was awarded to LoQus23 Therapeutics Ltd, a biotech company based in Cambridge UK. The venture capital group Forbion led the round, alongside existing investors SV Health Investors’ Dementia Discovery Fund and the Novartis Venture Fund.
